Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 6, p. 2862, doi. 10.1007/s12325-022-02126-0
- By:
- Publication type:
- Article
Works by Pitou, Celine
Results: 6
1
2
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.
- Published in:
- International Journal of Oncology, 2014, v. 45, n. 6, p. 2221, doi. 10.3892/ijo.2014.2679
- By:
- Publication type:
- Article
3
Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS).
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 3, p. 1074, doi. 10.1111/bcp.15034
- By:
- Publication type:
- Article
4
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
- Published in:
- AAPS Journal, 2019, v. 21, n. 2, p. 1, doi. 10.1208/s12248-018-0291-9
- By:
- Publication type:
- Article
5
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1145, doi. 10.1007/s10637-019-00873-6
- By:
- Publication type:
- Article
6
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2
- By:
- Publication type:
- Article